Introduction: Selection of resistance mutations on antiretroviral therapy (ART) including darunavir (DRV/r) or atazanavir (ATV/r) has been reported infrequently but mainly in clinical trials where patients were followed very frequently (at least four to five clinical visits and viral load measurements per year). The aim of this study was to evaluate the rate of resistance at failure and mutational patterns emerging in patients receiving DRV/r or ATV/r based-regimen as first line treatment and followed in standard clinical practice with less clinical visits and viral load measurements (median 02 per year). Methods: We studied 1,518 patients starting their first line antiretroviral therapy and followed during at least two years (n 0799 TVD'DRV/r, n070 KVX'DRV/r, n0618 TVD'ATV/r, n 031 KVX'ATV/r). The median viral load at baseline was 76,000 copies/mL and the median CD4 cell count 384 cell/mm
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